Clinical Practice Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Mar 7, 2018; 24(9): 1035-1045
Published online Mar 7, 2018. doi: 10.3748/wjg.v24.i9.1035
Table 4 Clinical characteristics of monogenic very-early-onset inflammatory bowel disease patients
PatientSexDisease onsetZ-score of heightZ-score of body weightChief complaintsOthersDisease locations and behaviorClinical and genetic diagnosisIntestinal surgeryTreatmentPrognosis
1M< 1 mo0.22-1.18Diarrhea, bloody stoolsPyodermaL2, P, B2B3CD, IL10RB mutationColostomySteroid, IFX, thalidomide, 6-MP/MTX/AZARemission
2F4 mo-1.76-0.96Diarrhea, bloody stoolsPyodermaL2,L4b, P, B2B3CD, IL10RA mutationIntestinal perforation repair, colostomy and J-POUCHSteroid, mesalazine, IFX, MTX/CsARemission
3M1 mo+-0.79-2.21Diarrhea, bloody stoolsElevation of ALTL2, P, B2CD, IL10RA mutationNoneNoneWaiting HSCT
4M1 mo+-3.11-3.66Diarrhea, bloody stoolsNoneL2, P, B1IBDU, IL10RA mutationNoneAntibioticsGive up
5M11 d-4.92-3.38Diarrhea, bloody stoolsNECL2,L4b, P, B1CD, IL10RA mutationNoneSteroids, AZAGive up
6M< 1 mo0.46-1.08Diarrhea, bloody stoolsEpilepsyL2, P, B1IBDU, CGDNoneNoneRemission
7M< 1 mo-0.84-2.04Persistent feverIntestinal malrotation, elevation of ALTL2, P, B1IBDU, CGDNoneNoneDead
8M9 mo-4.63-2.95Diarrhea, bloody stoolsHepatosplenomegalyL2, B1CD, CVIDIntestinal resection and anastomosisSteroid, 6MP, mesalazine, thalidomidePartial remission
9M5 yr 11 mo-2.2-1.57Abdominal pain, diarrhea, bloody stoolsNoneL2, L4bCD, XIAP deficiencyNoneDXM, IFX, 6MP/AZARemission